Gastrointestinal Cancer

Oncology
8
Pipeline Programs
10
Companies
10
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
3
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
3100%
+ 7 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Auron Therapeutics
1 program
1
AMT2003Phase 2/31 trial
Active Trials
NCT00332280TerminatedEst. Mar 2010
DS
Daiichi SankyoChina - Shanghai
2 programs
1
1
Raludotatug DeruxtecanPhase 2ADC1 trial
Patritumab deruxtecanPhase 1/2ADC1 trial
Active Trials
NCT06596694Recruiting180Est. Dec 2028
NCT06864169Active Not Recruiting160Est. Jan 2029
Swedish Orphan Biovitrum
1 program
1
AvatrombopagPhase 21 trial
Active Trials
NCT05772546Active Not RecruitingEst. Jul 2026
M&
Merck & Co.RAHWAY, NJ
1 program
1
Raludotatug DeruxtecanPhase 2ADC
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 765049Phase 11 trial
Active Trials
NCT06091930Recruiting97Est. Sep 2028
A
ArbeleChina - Hong Kong
1 program
1
CabotamigPhase 11 trial
Active Trials
NCT05411133RecruitingEst. May 2026
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
CapecitabinePhase 12 trials
Active Trials
NCT06065371Recruiting20Est. May 2027
NCT05568095Active Not Recruiting1,040Est. Jun 2026
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
Nutrition EmulsionN/A1 trial
Active Trials
NCT05606848Recruiting350Est. Mar 2025
Bristol Myers Squibb
1 program
SURGEN/A1 trial
Active Trials
NCT05375643Recruiting210Est. Jul 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Gilead SciencesCapecitabine
Auron TherapeuticsAMT2003
Daiichi SankyoRaludotatug Deruxtecan
Swedish Orphan BiovitrumAvatrombopag
Daiichi SankyoPatritumab deruxtecan
Gilead SciencesCapecitabine
Boehringer IngelheimBI 765049
ArbeleCabotamig
Bristol Myers SquibbSURGE
Fresenius KabiNutrition Emulsion

Clinical Trials (10)

Total enrollment: 2,057 patients across 10 trials

NCT05568095Gilead SciencesCapecitabine

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Start: Nov 2022Est. completion: Jun 20261,040 patients
Phase 3Active Not Recruiting
NCT00332280Auron TherapeuticsAMT2003

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Start: May 2006Est. completion: Mar 2010
Phase 2/3Terminated
NCT06864169Daiichi SankyoRaludotatug Deruxtecan

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Start: Apr 2025Est. completion: Jan 2029160 patients
Phase 2Active Not Recruiting
NCT05772546Swedish Orphan BiovitrumAvatrombopag

Avatrombopag vs. Placebo for CIT in GI Malignancies

Start: Nov 2023Est. completion: Jul 2026
Phase 2Active Not Recruiting
NCT06596694Daiichi SankyoPatritumab deruxtecan

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Start: Nov 2024Est. completion: Dec 2028180 patients
Phase 1/2Recruiting
NCT06065371Gilead SciencesCapecitabine

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Start: Nov 2024Est. completion: May 202720 patients
Phase 1Recruiting
NCT06091930Boehringer IngelheimBI 765049

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Start: Feb 2024Est. completion: Sep 202897 patients
Phase 1Recruiting
NCT05411133ArbeleCabotamig

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Start: May 2022Est. completion: May 2026
Phase 1Recruiting
NCT05375643Bristol Myers SquibbSURGE

SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)

Start: Apr 2023Est. completion: Jul 2028210 patients
N/ARecruiting
NCT05606848Fresenius KabiNutrition Emulsion

To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer

Start: Nov 2022Est. completion: Mar 2025350 patients
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 actively recruiting trials targeting 2,057 patients
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)